We are monitoring the impact of COVID-19 on Immunotherapy Drugs Market Get in touch with us for detailed analysis Know More
Pulished Date February, 2020
ID: 1092
Share on
Share on

Global Immunotherapy Drugs Market Size, Share, Trends and Growth Analysis Report – Segmented By Drug Type (Monoclonal antibodies, Interferons, Interleukins, Vaccines, checkpoint inhibitors), Application and Region - Industry Forecast | 2020 to 2025

Pulished: February, 2020
ID: 1092
Pages: 175

Immunotherapy Drugs Market Size, Growth (2020 to 2025)

As per our research analysis, the size of the global immunotherapy drugs market is estimated to hold USD 83.52 billion in 2020 and forecasted to grow USD 137.59 billion by 2024 with a significant CAGR of 10.5% during the forecast period.

Immunotherapy is a biological therapy used for treating cancer patients. The global immunotherapy drugs market is driven by factors like the quick approval process of drugs, an increase in the adoption of targeted therapies, and a high rise in lifestyle diseases. Immunotherapy is a treatment done to restore or stimulate the ability of defence system (immune system) to fight infection and disease. Biological therapy which is also called as immune therapy is a form of treatment using the natural ability of body that constitute the immune system to fight against disease and also protects the body from other side effects. Immunotherapy always has a vital role in the process of treatment of vulnerable diseases.

COVID-19 impact on the global immunotherapy drugs market

COVID 19, which is termed after the novel virus corona, has the most significant demand for immune therapy drugs. As seen from the last few months, immunocompromised persons are one’s got effected more for this virus. Immunotherapy drugs help to fight with external foreign factors attacking the body. Immunotherapy drugs cover types of monoclonal antibodies, adult vaccines, checkpoint inhibitors, and Alpha and beta interleukins.

MARKET DRIVERS

Growing prevalence of Cancer and accelerating aging population around the world are majorly increasing the demand for immunotherapy drugs.

According to the WHO, in 2016, nearly 1.75 million cancer patients are discovered in the U.S. only. According to the CDC, almost 1.5 million people are examined with cancer every year in the U.S. and more than lakhs of people are striving hard to survive due to cancer. One of the main factors that lead to lung cancer is smoking and consumption of alcohol, where 90% of men and 80% of women are suffering. Reports say that out of 6 patients, one patient die due to this cancer. The immunity system is made up of WBC, which helps the body to fight against the diseases and make the body stay healthy. There are different types of immunotherapies which are used for the treatment of cancer disease.

The U.S FDA has accepted 32 new drugs for different immunotherapies for the patients who are fighting with cancer like melanoma, breast cancer, lung cancer, kidney cancer, breast cancer etc. Immune-modulators, cell-based immunotherapies and vaccines are some of the treatments for cancer therapy.

Increase in options in the existing markets, and immunotherapy is another possibility to chemotherapy for the first-line treatment is the factors that support the growth of the Global Immunotherapy Drugs Market and also in the key players in the coming future. Next-generation treatment options offer the opportunity for new upcoming and improved techniques of anti-cancer therapy. Critical areas of possibility in this market include developing countries and growing adoption of immunotherapy.

MARKET RESTRAINTS

The high cost of the treatment of immunotherapy and high reduction of strength and effectiveness, the rate of the product development cycle is hindering the market growth. Lack of knowing immunotherapy drugs and also overall costly treatment is restraining the market. Side effects of immunotherapy on another body are supposed to limit the growth of the global immunotherapy drugs market.

The challenge of immunotherapy is to improve the effectiveness and patient, responsive rates. Additional makers would help to find a way to challenges posed by tumour heterogeneity because of the probability of targeting more than one type of cell to recognize multiple types of antigens. The high cost of the products is one of the significant challenges to the Global Immunotherapy Drugs Market.

REPORT COVERAGE

REPORT METRIC

DETAILS

Market Size Available

2019 to 2025

Base Year

2019

Forecast Period

2020 to 2025

Segments Analysed

By Drug Type, Application, and Region

Various Analyses Covered

Global, Regional & Country Level Analysis, Segment-Level Analysis, Drivers, Restraints, Opportunities, Challenges, PESTLE Analysis, Porter’s Five Forces Analysis, Competitive Landscape, Analyst Overview on Investment Opportunities

Regions Analysed

North America, Europe, Asia Pacific, Latin America, Middle East and Africa

 

This research report on the global immunotherapy drugs market has been segmented and sub-segmented based on the by drug type, application, and region.

Immunotherapy Drugs Market - By Drug Type:

Based on drug type, Monoclonal antibodies are among the most in-demand models of immunotherapy drugs that are likely to register the highest growth rate in the coming years. The Monoclonal Antibodies segment is expected to have the most massive share market value. It is attributed to growing regular approvals and higher ability to produce the desired result. This segment has the largest share due to the growing amount of funds which is used for the research and development and also used for treating cancer patients. This segment has a CAGR value of 7.25% during the period.

Immunotherapy Drugs Market - By Application:

  • Blood Cancer
  • Cervical Cancer
  • Breast Cancer
  • Glioblastoma
  • Lung Cancer
  • Gastric Cancer
  • Prostate Cancer
  • Melanoma

Based on the Application type, all kinds of Lung Cancer segment are accounted to hold the largest share in the market. The Application segment consists of the types of cancer in which the lung cancer holds the highest share sue to increase of lung cancer patients. Patients support these cancer treatments as they have very fewer side effects that can accelerate the growth of immunotherapy drugs market.

Immunotherapy Drugs Market - By Region:

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa

The North American region is expected to have the largest share market and is likely to continue over the period. The largest share in this region is due to supportable reimbursement policies; increasing combining of research institutes and the companies is one of the reasons for the growth of this region.

Europe is followed by North America region and is likely to grow with is a short period during the period attributed due to adoption of advanced cancer therapeutics for the effective treatment.

The Asia-Pacific is likely to have faster growth in the upcoming years. It is due to the occurrence of the rapid development of healthcare technology, large patient population and large amount spent on healthcare, high disposable income, increase in health and hygiene associated with awareness.

Latin America is likely to have an average amount of growth due to the existing pharmaceutical manufacturers in this region. The increase in this region is due to the growing existence of major pharmaceutical producers in the countries of this region.

TOP COMPANIES IN THE MARKET

List of key market participants leading the global immunotherapy drugs market profiled in this report are Merck, Roche, Eli Lilly, Amgen, Novartis, Celgene, AstraZeneca, Bristol Myers Squibb, GlaxoSmithKline PLC and Seattle Genetics.

RECENT MARKET DEVELOPMENTS

On January 07, 2019, Alligator Biosciences announced the launch of a novel concept in bispecific antibody formats RUBY. The ability to give generative therapeutic antibodies that are both efficient and highly manufacturable. 

On November 21, 2019, Myriad Genetics announced that Japan’s Health, Welfare, and Labor had approved the BRAS Analysis Diagnostic system that to help physicians determine which women with breast cancer and have Hereditary Breast and Ovarian Cancer syndrome. 

On December 30, 2019, The US FDA approved AstraZeneca Lynparza and Myriad Genetics’ CDx for BRCA as a maintenance treatment for certain metastatic pancreatic cancer patients. 

On November 11, 2019, Myriad Genetics presents new test Data in the Autoimmune system at Annual Meeting in Atlanta, GA. 

On October 23, 2019, The U.S. FDA, expanded the approval for GSK’s as a fourth-or later line treatment option for the advanced ovarian, fallopian tube, or primary peritoneal cancer patients who have homologous recombination deficiency. 

  1. Introduction

                1.1 Market Definition                    

                1.2 Study Deliverables                  

                1.3 Base Currency, Base Year and Forecast Periods                           

                1.4 General Study Assumptions                

  1. Research Methodology

                2.1 Introduction                              

                2.2 Research Phases                      

                                2.2.1 Secondary Research            

                                2.2.2 Primary Research 

                                2.2.3 Econometric Modelling     

                                2.2.4 Expert Validation  

                2.3 Analysis Design                         

                2.4 Study Timeline                          

  1. Overview

                3.1 Executive Summary                

                3.2 Key Inferences                         

  1. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)

                4.1 Market Drivers                          

                4.2 Market Restraints                    

                4.3 Key Challenges                         

                4.4 Current Opportunities in the Market               

  1. Market Segmentation

                5.1 By Drug Type                             

                                5.1.1 Monoclonal Antibodies     

                                5.1.2 Interferons             

                                5.1.3 Interleukins            

                                5.1.4 Vaccines  

                                5.1.5 Checkpoint Inhibitors         

                5.2 By Application                           

                                5.2.1 Blood Cancer         

                                5.2.2 Cervical Cancer     

                                5.2.3 Breast Cancer        

                                5.2.4 Glioblastoma         

                                5.2.5 Lung Cancer           

                                5.2.6 Gastric Cancer       

                                5.2.7 Prostate Cancer    

                                5.2.8 Melanoma              

  1. Geographical Analysis

                6.1 North America                          

                                6.1.1 Introduction           

                                6.1.2 United States         

                                6.1.3 Canada     

                6.2 Europe                         

                                6.2.1 Introduction           

                                6.2.2 U.K             

                                6.2.3 Spain         

                                6.2.4 Germany 

                                6.2.5 Italy           

                                6.2.6 France      

                6.3 Asia-Pacific                 

                                6.3.1 Introduction           

                                6.3.2 China         

                                6.3.3 India          

                                6.3.4 Japan        

                                6.3.5 South Korea           

                                6.3.6 Australia  

                6.4 Latin America                            

                                6.4.1 Introduction           

                                6.4.2 Brazil         

                                6.4.3 Mexico     

                                6.4.4 Argentina

                                6.4.5 Rest of Latin America         

                6.5 Middle East & Africa               

                                6.5.1 Introduction           

                                6.5.2 Middle-East            

                                6.5.3 Africa        

  1. Pipeline Product Analysis

                7.1 Overview                                    

                7.2 Pipeline Development Landscape                                     

                7.3 Molecular Targets in the Pipeline                                     

                7.4 Clinical Trials                              

                                7.4.1 Failure Rate by Stage of Development, Indication, Molecule Type and Molecular Target       

                                7.4.2 Clinical Trial Duration by Stage of Development, Indication, Molecule Type and Molecular Target                 

                                7.4.3 Clinical Trial Size by Stage of Development, Indication, Molecule Type and Molecular Target.               

  1. Strategic Analysis

                8.1 PESTLE analysis                         

                                8.1.1 Political     

                                8.1.2 Economic 

                                8.1.3 Social         

                                8.1.4 Technological         

                                8.1.5 Legal          

                                8.1.6 Environmental      

                8.2 Porter’s Five analysis                              

                                8.2.1 Bargaining Power of Suppliers        

                                8.2.2 Bargaining Power of Consumers    

                                8.2.3 Threat of New Entrants     

                                8.2.4 Threat of Substitute Products and Services

                                8.2.5 Competitive Rivalry within the Industry      

  1. Market Leaders' Analysis

                9.1 Eli Lilly                           

                                9.1.1 Overview

                                9.1.2 Product Analysis   

                                9.1.3 Financial analysis  

                                9.1.4 Recent Developments       

                                9.1.5 SWOT analysis       

                                9.1.6 Analyst View          

                9.2 Merck                           

                9.3 Roche                           

                9.4 Amgen                         

                9.5 Novartis                       

                9.6 Celgene                       

                9.7 AstraZeneca               

                9.8 Bristol Myers Squibb                              

                9.9 GlaxoSmithKline PLC                              

                9.10 Seattle Genetics                    

  1. Competitive Landscape

                10.1 Market share analysis                          

                10.2 Merger and Acquisition Analysis                     

                10.3 Agreements, collaborations and Joint Ventures                       

                10.4 New Product Launches                       

  1. Market Outlook and Investment Opportunities

Appendix                                           

  1. a) List of Tables
  2. b) List of Figures
  • Global, Regional and country-level analysis and forecasts of the study market; providing Insights on the major countries/regions in which this industry is blooming and to also identify the regions that are still untapped
  • Segment-level analysis in terms of technology, component, and type along with market size forecasts and estimations to detect key areas of industry growth in detail
  • Identification of key drivers, restraints, opportunities, and challenges (DROC) in the market and their impact on shifting market dynamics
  • Study of the effect of exogenous and endogenous factors that affect the global market; which includes broadly demographic, economics, and political, among other macro-environmental factors presented in an extensive PESTLE Analysis
  • Study the micro environment factors that determine the overall profitability of an Industry, using Porter’s five forces analysis for analysing the level of competition and business strategy development
  • A comprehensive list of key market players along with their product portfolio, current strategic interests, key financial information, legal issues, SWOT analysis and analyst overview to study and sustain the market environment
  • Competitive landscape analysis listing out the mergers, acquisitions, collaborations in the field along with new product launches, comparative financial studies and recent developments in the market by the major companies
  • An executive summary, abridging the entire report in such a way that decision-making personnel can rapidly become acquainted with background information, concise analysis and main conclusions
  • Expertly devised analyst overview along with Investment opportunities to provide both individuals and organizations a strong financial foothold in the market

 

  1. Global Immunotherapy Drugs Market By Region, From 2020 to 2025 (USD Billion)
  2. Global Immunotherapy Drugs Market By Drug Type, From 2020 to 2025 (USD Billion)
  3. Global Monoclonal Antibodies Market By Region, From 2020 to 2025 (USD Billion)
  4. Global Interferons Market By Region, From 2020 to 2025 (USD Billion)
  5. Global Interleukins Market By Region, From 2020 to 2025 (USD Billion)
  6. Global Vaccines Market By Region, From 2020 to 2025 (USD Billion)
  7. Global Checkpoint Inhibitors Market By Region, From 2020 to 2025 (USD Billion)
  8. Global Immunotherapy Drugs Market By Application, From 2020 to 2025 (USD Billion)
  9. Global Blood Cancer Market By Region, From 2020 to 2025 (USD Billion)
  10. Global Cervical Cancer Market By Region, From 2020 to 2025 (USD Billion)
  11. Global Breast Cancer Market By Region, From 2020 to 2025 (USD Billion)
  12. Global Glioblastoma Market By Region, From 2020 to 2025 (USD Billion)
  13. Global Lung Cancer Market By Region, From 2020 to 2025 (USD Billion)
  14. Global Gastric Cancer Market By Region, From 2020 to 2025 (USD Billion)
  15. Global Prostate Cancer Market By Region, From 2020 to 2025 (USD Billion)
  16. Global Melanoma Market By Region, From 2020 to 2025 (USD Billion)
  17. North America Immunotherapy Drugs Market By Region, From 2020 to 2025 (USD Billion)
  18. North America Immunotherapy Drugs Market By Drug Type, From 2020 to 2025 (USD Billion)
  19. North America Monoclonal Antibodies Market By Region, From 2020 to 2025 (USD Billion)
  20. North America Interferons Market By Region, From 2020 to 2025 (USD Billion)
  21. North America Interleukins Market By Region, From 2020 to 2025 (USD Billion)
  22. North America Vaccines Market By Region, From 2020 to 2025 (USD Billion)
  23. North America Checkpoint Inhibitors Market By Region, From 2020 to 2025 (USD Billion)
  24. North America Immunotherapy Drugs Market By Application, From 2020 to 2025 (USD Billion)
  25. North America Blood Cancer Market By Region, From 2020 to 2025 (USD Billion)
  26. North America Cervical Cancer Market By Region, From 2020 to 2025 (USD Billion)
  27. North America Breast Cancer Market By Region, From 2020 to 2025 (USD Billion)
  28. North America Glioblastoma Market By Region, From 2020 to 2025 (USD Billion)
  29. North America Lung Cancer Market By Region, From 2020 to 2025 (USD Billion)
  30. North America Gastric Cancer Market By Region, From 2020 to 2025 (USD Billion)
  31. North America Prostate Cancer Market By Region, From 2020 to 2025 (USD Billion)
  32. North America Melanoma Market By Region, From 2020 to 2025 (USD Billion)
  33. Europe Immunotherapy Drugs Market By Region, From 2020 to 2025 (USD Billion)
  34. Europe Immunotherapy Drugs Market By Drug Type, From 2020 to 2025 (USD Billion)
  35. Europe Monoclonal Antibodies Market By Region, From 2020 to 2025 (USD Billion)
  36. Europe Interferons Market By Region, From 2020 to 2025 (USD Billion)
  37. Europe Interleukins Market By Region, From 2020 to 2025 (USD Billion)
  38. Europe Vaccines Market By Region, From 2020 to 2025 (USD Billion)
  39. Europe Checkpoint Inhibitors Market By Region, From 2020 to 2025 (USD Billion)
  40. Europe Immunotherapy Drugs Market By Application, From 2020 to 2025 (USD Billion)
  41. Europe Blood Cancer Market By Region, From 2020 to 2025 (USD Billion)
  42. Europe Cervical Cancer Market By Region, From 2020 to 2025 (USD Billion)
  43. Europe Breast Cancer Market By Region, From 2020 to 2025 (USD Billion)
  44. Europe Glioblastoma Market By Region, From 2020 to 2025 (USD Billion)
  45. Europe Lung Cancer Market By Region, From 2020 to 2025 (USD Billion)
  46. Europe Gastric Cancer Market By Region, From 2020 to 2025 (USD Billion)
  47. Europe Prostate Cancer Market By Region, From 2020 to 2025 (USD Billion)
  48. Europe Melanoma Market By Region, From 2020 to 2025 (USD Billion)
  49. Asia-Pacific Immunotherapy Drugs Market By Region, From 2020 to 2025 (USD Billion)
  50. Asia-Pacific Immunotherapy Drugs Market By Drug Type, From 2020 to 2025 (USD Billion)
  51. Asia-Pacific Monoclonal Antibodies Market By Region, From 2020 to 2025 (USD Billion)
  52. Asia-Pacific Interferons Market By Region, From 2020 to 2025 (USD Billion)
  53. Asia-Pacific Interleukins Market By Region, From 2020 to 2025 (USD Billion)
  54. Asia-Pacific Vaccines Market By Region, From 2020 to 2025 (USD Billion)
  55. Asia-Pacific Checkpoint Inhibitors Market By Region, From 2020 to 2025 (USD Billion)
  56. Asia-Pacific Immunotherapy Drugs Market By Application, From 2020 to 2025 (USD Billion)
  57. Asia-Pacific Blood Cancer Market By Region, From 2020 to 2025 (USD Billion)
  58. Asia-Pacific Cervical Cancer Market By Region, From 2020 to 2025 (USD Billion)
  59. Asia-Pacific Breast Cancer Market By Region, From 2020 to 2025 (USD Billion)
  60. Asia-Pacific Glioblastoma Market By Region, From 2020 to 2025 (USD Billion)
  61. Asia-Pacific Lung Cancer Market By Region, From 2020 to 2025 (USD Billion)
  62. Asia-Pacific Gastric Cancer Market By Region, From 2020 to 2025 (USD Billion)
  63. Asia-Pacific Prostate Cancer Market By Region, From 2020 to 2025 (USD Billion)
  64. Asia-Pacific Melanoma Market By Region, From 2020 to 2025 (USD Billion)
  65. Latin America Immunotherapy Drugs Market By Region, From 2020 to 2025 (USD Billion)
  66. Latin America Immunotherapy Drugs Market By Drug Type, From 2020 to 2025 (USD Billion)
  67. Latin America Monoclonal Antibodies Market By Region, From 2020 to 2025 (USD Billion)
  68. Latin America Interferons Market By Region, From 2020 to 2025 (USD Billion)
  69. Latin America Interleukins Market By Region, From 2020 to 2025 (USD Billion)
  70. Latin America Vaccines Market By Region, From 2020 to 2025 (USD Billion)
  71. Latin America Checkpoint Inhibitors Market By Region, From 2020 to 2025 (USD Billion)
  72. Latin America Immunotherapy Drugs Market By Application, From 2020 to 2025 (USD Billion)
  73. Latin America Blood Cancer Market By Region, From 2020 to 2025 (USD Billion)
  74. Latin America Cervical Cancer Market By Region, From 2020 to 2025 (USD Billion)
  75. Latin America Breast Cancer Market By Region, From 2020 to 2025 (USD Billion)
  76. Latin America Glioblastoma Market By Region, From 2020 to 2025 (USD Billion)
  77. Latin America Lung Cancer Market By Region, From 2020 to 2025 (USD Billion)
  78. Latin America Gastric Cancer Market By Region, From 2020 to 2025 (USD Billion)
  79. Latin America Prostate Cancer Market By Region, From 2020 to 2025 (USD Billion)
  80. Latin America Melanoma Market By Region, From 2020 to 2025 (USD Billion)
  81. Middle East & Africa Immunotherapy Drugs Market By Region, From 2020 to 2025 (USD Billion)
  82. Middle East & Africa Immunotherapy Drugs Market By Drug Type, From 2020 to 2025 (USD Billion)
  83. Middle East & Africa Monoclonal Antibodies Market By Region, From 2020 to 2025 (USD Billion)
  84. Middle East & Africa Interferons Market By Region, From 2020 to 2025 (USD Billion)
  85. Middle East & Africa Interleukins Market By Region, From 2020 to 2025 (USD Billion)
  86. Middle East & Africa Vaccines Market By Region, From 2020 to 2025 (USD Billion)
  87. Middle East & Africa Checkpoint Inhibitors Market By Region, From 2020 to 2025 (USD Billion)
  88. Middle East & Africa Immunotherapy Drugs Market By Application, From 2020 to 2025 (USD Billion)
  89. Middle East & Africa Blood Cancer Market By Region, From 2020 to 2025 (USD Billion)
  90. Middle East & Africa Cervical Cancer Market By Region, From 2020 to 2025 (USD Billion)
  91. Middle East & Africa Breast Cancer Market By Region, From 2020 to 2025 (USD Billion)
  92. Middle East & Africa Glioblastoma Market By Region, From 2020 to 2025 (USD Billion)
  93. Middle East & Africa Lung Cancer Market By Region, From 2020 to 2025 (USD Billion)
  94. Middle East & Africa Gastric Cancer Market By Region, From 2020 to 2025 (USD Billion)
  95. Middle East & Africa Prostate Cancer Market By Region, From 2020 to 2025 (USD Billion)
  96. Middle East & Africa Melanoma Market By Region, From 2020 to 2025 (USD Billion)

Please wait. . . . Your request is being processed

Related Reports

LICENCE TYPE

$ 1234 4255

Clients
clients
clients
clients
clients
clients
clients
Click for Request Sample